Marina Pajic

University of Sydney — Australia

Medicine · Health Sciences

62h-index39.4kcitations359works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic and Hepatic Oncology Research(146), Cancer Genomics and Diagnostics(106), Cancer, Hypoxia, and Metabolism(40), Ferroptosis and cancer prognosis(33), Neuroendocrine Tumor Research Advances(28)

Publications307 total

Supplementary Table S11 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma
2025Open Access
Data from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma
2025Open Access
Supplementary Fig. S1 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma
2025Open Access
Supplementary Table S10 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma
2025Open Access
Supplementary Table S4 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma
2025Open Access
Supplementary Fig. S4 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma
2025Open Access
Supplementary Table S9 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma
2025Open Access
Supplementary Table S1 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma
2025Open Access
Supplementary Fig. S3 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma
2025Open Access
Supplementary Fig. S5 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma
2025Open Access
Supplementary Fig. S6 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma
2025Open Access
Supplementary Fig. S2 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma
2025Open Access
Supplementary Table S3 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma
2025Open Access
Supplementary Table S8 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma
2025Open Access
Supplementary Table S2 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma
2025Open Access
Supplementary Table S7 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma
2025Open Access
Supplementary Table S6 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma
2025Open Access
Supplementary Table S5 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in <i>TFCP2</i> Fusion–Defined Rhabdomyosarcoma
2025Open Access
Supplementary Table 3 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
2025Open Access
Supplementary Figure 11 from Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification
2025Open Access
page 1 of 16Next →

Frequent Co-authors

Andrew V. Biankin(30), David K. Chang(24), Amber L. Johns(23), Anthony J. Gill(22), Mark Pinese(21), Mark J. Cowley(18), Angela Chou(18), Jaswinder S. Samra(18), Venessa Chin(17), Lorraine A. Chantrill(16), Adnan Nagrial(16), Nicola Waddell(15), Sean M. Grimmond(15), Paul Timpson(15), Jeremy L. Humphris(14), Elizabeth A. Musgrove(14), Jianmin Wu(13), Marc D. Jones(13), Christopher J. Scarlett(12), James G. Kench(12)